Wuxi Wuxi Pharmaceutical Co., Ltd. and Lilai Pharmaceutical Co., Ltd. jointly develop new small molecule drugs for cardiovascular diseases

Wuxi apptec and Lilly pharmaceutical announced strategic cooperation, and both sides will work together to develop, produce and commercialize a new small molecule drug in China The drug is an innovative, once-a-day oral preparation developed by Lilly to deal with the risk of cardiovascular disease in patients with dyslipidemia, which is a global medical problem to be solved urgently It is estimated that there are 276 million people with dyslipidemia in China, of which about 12 million patients need to receive medication The new drug aims to reduce the risk of cardiovascular disease in patients with LDL cholesterol and triglyceride elevation According to the agreement, Wuxi apptec will be responsible for the registration, development and production of the drug in China, led by the product development service and cooperation (pdsp) division of Wuxi apptec The drug will be produced by Wuxi apptec in China to support drug development in China Lilly will be responsible for the marketing of the drug The two sides will jointly invest to bring this potential innovative drug to Chinese patients Further financial terms of the cooperation have not been disclosed Wuxi apptec will be responsible for submitting the application for clinical trials of new drugs (ind) in China, and product development and registration will also be carried out in China "We are very pleased to work with Wuxi apptec to develop this potential innovative drug," said Andrew Hodge, President of Lilly China "As part of Lilly's concept of" taking root in China and benefiting China ", this unique cooperation will combine Lilly's world leading technology with Wuxi apptec's rich local experience and expertise, and will better benefit the needs of patients in China and around the world," said Mr "Wuxi Pharmaceutical Co., Ltd is very pleased to carry out strategic cooperation with Lilly, a leading pharmaceutical company in the world, to jointly develop, register and produce this potential global first new drug," said Dr Li Ge, chairman and chief executive officer of Wuxi Pharmaceutical Co., Ltd "the Chinese government recently announced a series of measures to reform the drug review and approval system, and vigorously encouraged, supported and promoted the efforts to solve the major medical problems of the public Development and production of innovative drugs for therapeutic needs in China This strategic cooperation between Wuxi apptec and Lilly fully conforms to China's reform measures and development trend I hope that with the support of national policies and the joint efforts of both sides, this cooperation can bring good news to patients in China and around the world as soon as possible " About Wuxi Wuxi apptec is a laboratory R & D and production service company that operates in both China and the United States and provides all-round integration from drug discovery to marketization for global pharmaceutical companies, biotechnology companies and medical device companies With the purpose of taking research as the first task and customer as the center, Wuxi apptec helps global customers shorten the R & D cycle of drugs and medical devices and reduce the R & D cost through a cost-effective and efficient service platform, so as to benefit global patients For details, please visit the company's website: about Lilly, as a global leader in the medical and health industry, which is committed to rewarding patients with innovation and caring for life Since its establishment for more than 100 years, we have always adhered to the concept of providing patients with the best quality drugs with the latest technology, which is in line with the commitment of the company's founder Colonel Lilly Today, we are still committed to this mission and carry out various work accordingly Lilly people all over the world not only devote themselves to the research and development of life-saving drugs, actively help patients better understand and manage diseases, but also give back to the society wholeheartedly through charity activities To learn more about Lilly pharmaceuticals, please visit and http: / / Com.